Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Strong Early Promise For Takeda 'Off The Shelf' CAR-NK Therapy

Successful, Safe And Simple Alternative?

Executive Summary

Highly promising results for a novel, easy to use form of CAR therapy, as early trial in hematologic malignancies shows a high response and low toxicity.

You may also be interested in...



Takeda Buys Out Partner GammaDelta In Cell Therapy Push

Japanese major buys out existing cancer cell therapy research partner, exercising an exclusive option dating back to a 2017 collaboration and expanding its immuno-oncology ambitions and pipeline.

Fate’s Phase I NK Cell Therapy Sparks Optimism, But Longer Follow-Up Needed

While the data are early, they have also generated positive views toward the company’s pipeline ahead of an anticipated CAR-NK data announcement at its investor meeting.

Could Outpatient Cell Therapies Provide Way Out Of Bundled Payment Trap?

Giving cell therapies as outpatient rather than inpatient treatments could be a way around the need for bundled payments, but it’s not universally applicable.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC141635

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel